Advertisement

Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?

  • Linda Cucciniello
    Affiliations
    Department of Medicine (DAME), University of Udine, 33100 Udine, Italy

    Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
    Search for articles by this author
  • Lorenzo Gerratana
    Affiliations
    Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
    Search for articles by this author
  • Lucia Del Mastro
    Affiliations
    Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy

    Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy
    Search for articles by this author
  • Fabio Puglisi
    Correspondence
    Corresponding author at: Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. Unit of Medical Oncology and Cancer Prevention, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy.
    Affiliations
    Department of Medicine (DAME), University of Udine, 33100 Udine, Italy

    Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy
    Search for articles by this author
Published:August 04, 2022DOI:https://doi.org/10.1016/j.ctrv.2022.102445

      Highlights

      • Adjuvant endocrine therapy represents the cornerstone for the management of hormone receptor positive, HER2 negative early breast cancer.
      • Five years of therapy with tamoxifen represent the standard of care for low-risk peri/premenopausal patients.
      • The combination of ovarian suppression with tamoxifen or an aromatase inhibitor should be considered for high-risk peri/premenopausal patients.
      • Postmenopausal patients, should receive an upfront aromatase inhibitor.
      • To high-risk patients, an extended strategy can be proposed both in the peri/premenopausal and postmenopausal settings with the addition of abemaciclib.

      Abstract

      Endocrine therapy represents the gold standard for the adjuvant treatment of luminal-like early breast cancer, but its personalization is still a major point of debate. To define the most appropriate therapeutic strategy, both the patient’s menopausal status at the moment of diagnosis and the individual risk of disease recurrence should be taken into account. Five years of therapy with tamoxifen represent the standard of care for low-risk pre/perimenopausal patients, whilst the combination of ovarian suppression with tamoxifen or an aromatase inhibitor should be considered for high-risk patients. Also, to high-risk patients, an extended strategy can be proposed. Postmenopausal patients, instead, should receive an upfront aromatase inhibitor and an extended strategy can be considered for a high risk of disease recurrence.
      Aim of this review is to set a focus on the major studies investigating the optimal type and duration of adjuvant endocrine therapy and evaluate emerging options.

      Keywords

      To read this article in full you will need to make a payment
      ESMO Member Login
      Login with your ESMO username and password.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2019.
        CA Cancer J Clin. 2019; 69: 7-34https://doi.org/10.3322/caac.21551
        • Goldhirsch A.
        • Wood W.C.
        • Gelber R.D.
        • Coates A.S.
        • Thürlimann B.
        • Senn H.-J.
        Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
        Ann Oncol. 2007; 18: 1133-1144https://doi.org/10.1093/annonc/mdm271
        • Voorwerk L
        • Horlings HM
        • Sanders J
        • Keusters MS
        • Cornelissen S
        • Sonke GS
        • et al.
        Immune landscape of breast tumors with low and intermediate estrogen receptor (ER) expression.
        J Clin Oncol. 2022; 40 (566–566)
        • Yoder R.
        • Kimler B.F.
        • Staley J.M.
        • Schwensen K.
        • Wang Y.Y.
        • Finke K.
        • et al.
        Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
        npj Breast Cancer. 2022; 8https://doi.org/10.1038/s41523-022-00448-4
        • Cardoso F.
        • Kyriakides S.
        • Ohno S.
        • Penault-Llorca F.
        • Poortmans P.
        • Rubio I.T.
        • et al.
        Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 1194-1220
        • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
        • Davies C
        • Godwin J
        • et al.
        Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
        Lancet. 2011; 378: 771-784
      1. The Rationale for Adjuvant Ovarian Suppression in Patients With Advanced Breast Cancer Following Chemotherapy. Evol Paradig Ovarian Suppr Breast Cancer 2019; 1(1).

        • Tevaarwerk A.J.
        • Wang M.
        • Zhao F.
        • Fetting J.H.
        • Cella D.
        • Wagner L.I.
        • et al.
        Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193, INT-0142): A Trial of the Eastern Cooperative Oncology Group.
        J Clin Oncol. 2014; 32: 3948-3958
        • Francis P.A.
        • Regan M.M.
        • Fleming G.F.
        • Láng I.
        • Ciruelos E.
        • Bellet M.
        • et al.
        Adjuvant Ovarian Suppression in Premenopausal Breast Cancer.
        N Engl J Med. 2015; 372: 436-446
        • Kim H.-A.
        • Lee J.W.
        • Nam S.J.
        • Park B.-W.
        • Im S.-A.
        • Lee E.S.
        • et al.
        Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial.
        J Clin Oncol. 2020; 38: 434-443
        • Francis P.A.
        • Pagani O.
        • Fleming G.F.
        • Walley B.A.
        • Colleoni M.
        • Láng I.
        • et al.
        Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
        N Engl J Med. 2018; 379: 122-137
        • Gnant M.
        • Mlineritsch B.
        • Stoeger H.
        • Luschin-Ebengreuth G.
        • Heck D.
        • Menzel C.
        • et al.
        Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
        Lancet Oncol. 2011; 12: 631-641
        • Perrone F.
        • De Laurentiis M.
        • De Placido S.
        • Orditura M.
        • Cinieri S.
        • Riccardi F.
        • et al.
        Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
        Eur J Cancer. 2019; 118: 178-186
        • Gnant M.
        • Mlineritsch B.
        • Stoeger H.
        • Luschin-Ebengreuth G.
        • Knauer M.
        • Moik M.
        • et al.
        Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
        Ann Oncol. 2015; 26: 313-320
      2. Regan MM, Walley BA, Fleming GF et al. Randomized comparisons of adjuvant aromatase inhibitor exemestane plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Update of the TEXT and SOFT trials. 2021 San Antonio Breast Cancer 2021.

        • Bradley R.
        • Braybrooke J.
        • Gray R.
        • Hills R.K.
        • Liu Z.
        • Pan H.
        • et al.
        Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
        LancetOncol. 2022; 23: 382-392
        • Regan M.M.
        • Francis P.A.
        • Pagani O.
        • Fleming G.F.
        • Walley B.A.
        • Viale G.
        • et al.
        Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials.
        J Clin Oncol. 2016; 34: 2221-2231
        • Yang G.
        • Nowsheen S.
        • Aziz K.
        • Georgakilas A.G.
        Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.
        Pharmacol Ther. 2013; 139: 392-404https://doi.org/10.1016/j.pharmthera.2013.05.005
        • Franzoi M.A.
        • Agostinetto E.
        • Perachino M.
        • Del Mastro L.
        • de Azambuja E.
        • Vaz-Luis I.
        • et al.
        Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer.
        LancetOncol. 2021; 22: e303-e313
        • Davies C.
        • Pan H.
        • Godwin J.
        • Gray R.
        • Arriagada R.
        • Raina V.
        • et al.
        Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
        Lancet. 2013; 381: 805-816
        • Gray RG
        • Rea D
        • Handley K
        • Bowden SJ
        • Perry P
        • Earl HM
        • et al.
        aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
        J Clin Oncol. 2013; 31 (5–5)
        • Goss P.E.
        Letrozole in the extended adjuvant setting: MA.17.
        Breast Cancer Res Treat. 2007; 105: 45-53https://doi.org/10.1007/s10549-007-9698-1
      3. Azim HA SA. Commentary on “aTTom”: long-term effects of continuing adjuvant Tamoxifen to 10 years. Chin Clin Oncol 2014; 3(1)7 n.d. https://doi.org/10.3978/j.issn.2304-3865.2013.12.02.

        • Goss P.E.
        • Ingle J.N.
        • Martino S.
        • Robert N.J.
        • Muss H.B.
        • Livingston R.B.
        • et al.
        Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole.
        Ann Oncol. 2013; 24: 355-361
        • Mamounas E.P.
        • Jeong J.-H.
        • Wickerham D.L.
        • Smith R.E.
        • Ganz P.A.
        • Land S.R.
        • et al.
        Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial.
        J Clin Oncol. 2008; 26: 1965-1971
        • Parisi F
        • Razeti MG
        • Blondeaux E
        • Arecco L
        • Perachino M
        • Tagliamento M
        • et al.
        Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer.
        Clin Med Insights Oncol. 2020; 14 (117955492093181)
      4. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
        Lancet. 2015; 386: 1341-1352
        • De Placido S.
        • Gallo C.
        • De Laurentiis M.
        • Bisagni G.
        • Arpino G.
        • Sarobba M.G.
        • et al.
        Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
        LancetOncol. 2018; 19: 474-485
        • Tjan-Heijnen V.C.G.
        • van Hellemond I.E.G.
        • Peer P.G.M.
        • Swinkels A.C.P.
        • Smorenburg C.H.
        • van der Sangen M.J.C.
        • et al.
        Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
        LancetOncol. 2017; 18: 1502-1511
        • Del Mastro L.
        • Mansutti M.
        • Bisagni G.
        • Ponzone R.
        • Durando A.
        • Amaducci L.
        • et al.
        Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
        LancetOncol. 2021; 22: 1458-1467
      5. Del Mastro L, Mansutti M, Bisagni G et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella. ESM0 Congr 2021 n.d.

      6. Ohtani S, Iijima K, Higaki K, Sato Y, Hozumi Y, Hasegawa Y, et al. Abstract GS3-04: A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study. Gen. Sess. Abstr., American Association for Cancer Research; 2019, p. GS3-04-GS3-04. https://doi.org/10.1158/1538-7445.SABCS18-GS3-04.

        • Mamounas E.P.
        • Bandos H.
        • Lembersky B.C.
        • Jeong J.-H.
        • Geyer C.E.
        • Rastogi P.
        • et al.
        Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2019; 20: 88-99
      7. Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE, Rastogi P, et al. Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who. Gen. Sess. Abstr., American Association for Cancer Research; 2020, p. GS4-01-GS4-01. https://doi.org/10.1158/1538-7445.SABCS19-GS4-01.

        • Gnant M.
        • Fitzal F.
        • Rinnerthaler G.
        • Steger G.G.
        • Greil-Ressler S.
        • Balic M.
        • et al.
        Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
        N Engl J Med. 2021; 385: 395-405
        • Blok EJ
        • Kroep JR
        • Meershoek-Klein Kranenbarg E
        • Duijm-de Carpentier M
        • Putter H
        • van den Bosch J
        • et al.
        Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
        JNCI J Natl Cancer Inst. 2018; 110: 40-48
        • Liefers G-J
        • Noordhoek I
        • Putter H
        • Wong J
        • Siuliukina N
        • Zhang Y
        • et al.
        Predictive performance of breast cancer index (BCI) and clinical treatment score post-5 years (CTS5) in the IDEAL study.
        J Clin Oncol. 2022; 40 (545–545)
        • Andre F.
        • Ismaila N.
        • Allison K.H.
        • Barlow W.E.
        • Collyar D.E.
        • Damodaran S.
        • et al.
        Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
        J Clin Oncol. 2022; 40: 1816-1837
        • Lipsyc-Sharf M.
        • de Bruin E.C.
        • Santos K.
        • McEwen R.
        • Stetson D.
        • Patel A.
        • et al.
        Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer.
        J Clin Oncol. 2022; 40: 2408-2419
        • Goss P.E.
        • Ingle J.N.
        • Pritchard K.I.
        • Robert N.J.
        • Muss H.
        • Gralow J.
        • et al.
        Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
        N Engl J Med. 2016; 375: 209-219
        • Perrone F.
        • Di Maio M.
        • Del Mastro L.
        A Case Where Switching the End Points for Clinical Trial Interpretation Might Be the Right Choice.
        JAMAOncol. 2017; 3: 735https://doi.org/10.1001/jamaoncol.2016.4896
        • Colleoni M.
        • Luo W.
        • Karlsson P.
        • Chirgwin J.
        • Aebi S.
        • Jerusalem G.
        • et al.
        Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
        LancetOncol. 2018; 19: 127-138
        • Sabnis GJ
        • Macedo LF
        • Goloubeva O
        • Schayowitz A
        • Brodie AMH
        Stopping Treatment Can Reverse Acquired Resistance to Letrozole.
        Cancer Res. 2008; 68: 4518-4524
        • Jerusalem G.
        • Farah S.
        • Courtois A.
        • Chirgwin J.
        • Aebi S.
        • Karlsson P.
        • et al.
        Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
        Ann Oncol. 2021; 32: 1256-1266
        • Piezzo M.
        • Chiodini P.
        • Riemma M.
        • Cocco S.
        • Caputo R.
        • Cianniello D.
        • et al.
        Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
        Int J Mol Sci. 2020; 21: 6400
        • Mayer E.L.
        • Dueck A.C.
        • Martin M.
        • Rubovszky G.
        • Burstein H.J.
        • Bellet-Ezquerra M.
        • et al.
        Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
        LancetOncol. 2021; 22: 212-222
        • Loibl S.
        • Marmé F.
        • Martin M.
        • Untch M.
        • Bonnefoi H.
        • Kim S.-B.
        • et al.
        Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial.
        J Clin Oncol. 2021; 39: 1518-1530
        • Harbeck N.
        • Rastogi P.
        • Martin M.
        • Tolaney S.M.
        • Shao Z.M.
        • Fasching P.A.
        • et al.
        Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
        Ann Oncol. 2021; 32: 1571-1581
        • Johnston S.R.D.
        • Harbeck N.
        • Hegg R.
        • Toi M.
        • Martin M.
        • Shao Z.M.
        • et al.
        Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
        J Clin Oncol. 2020; 38: 3987-3998
        • Kaufman B.
        • Shapira-Frommer R.
        • Schmutzler R.K.
        • Audeh M.W.
        • Friedlander M.
        • Balmaña J.
        • et al.
        Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation.
        J Clin Oncol. 2015; 33: 244-250
        • Tutt A.N.J.
        • Garber J.E.
        • Kaufman B.
        • Viale G.
        • Fumagalli D.
        • Rastogi P.
        • et al.
        Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer.
        N Engl J Med. 2021; 384: 2394-2405